Avadel Pharmaceuticals Plc ADR (AVDL) Stock Price, Quote & News

Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 a...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 353 1 901 5201

Website: www.avadel.com

Address:

10 Earlsfort Terrace, Dublin, Ireland

AnthonySaba79 Aug. 8 at 3:45 PM

$AVDL where is this going?

0 · Reply

BlancaAlbertson678 Aug. 8 at 3:14 PM

$AVDL Revenue est for 2025? $20M+ if momentum holds...W.K.S.P scaling right

0 · Reply

Otus Aug. 8 at 3:09 PM

$AVDL I would expect a flurry of upgrades next week. Would like to see some new coverage, positive of course. May not move the needle too much but will show the positivity of future earnings. Obviously that translates to a significantly higher share price if they meet those estimates.

0 · Reply

HoHoHoHum Aug. 8 at 1:23 PM

$AVDL should move and settle down in the 16+ area rather quickly

0 · Reply

Capitulation_0 Aug. 8 at 12:23 PM

$AVDL breaks 13s today.. should be trading north of $20. Taking market share. Suing JAZZ for lost revenue of 1B - probably settle for 500m range. 2nd indication in about a year. Jazz oxybate franchise did ~450m in Q2 alone.. Superior product should win out in time, even with this management. Should surpass 1B in few years, which is todays marketcap. Also, they became profitable.

1 · Reply

Jusar Aug. 8 at 11:17 AM

$AVDL Nice last minute purchase

0 · Reply

JarvisFlow Aug. 8 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Avadel Pharmaceuticals ( $AVDL ), setting the rating to Buy with a target price of 22 → 24.

0 · Reply

Mrmondial Aug. 8 at 8:13 AM

$AVDL amazing trick to be able to speak out of your a*s

0 · Reply

profitraider Aug. 8 at 4:59 AM

$AVDL Bankrupt in less than a year!

1 · Reply

Capitulation_0 Aug. 7 at 7:58 PM

$AVDL lol, hi shorties..13%. 12m shares

0 · Reply

Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 20 hours ago

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 7:00 AM EDT - 1 day ago

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

Jul 31, 2025, 8:00 AM EDT - 8 days ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

Jul 14, 2025, 7:00 AM EDT - 25 days ago

ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

Jun 30, 2025, 9:41 AM EDT - 5 weeks ago

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

Jun 30, 2025, 7:00 AM EDT - 5 weeks ago

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

Jun 29, 2025, 10:30 PM EDT - 5 weeks ago

ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports

Jun 29, 2025, 9:00 PM EDT - 5 weeks ago

An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure

Jun 5, 2025, 7:30 AM EDT - 2 months ago

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

May 29, 2025, 4:05 PM EDT - 2 months ago

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

May 29, 2025, 8:00 AM EDT - 2 months ago

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 11:43 AM EDT - 3 months ago

Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

May 13, 2025, 4:15 PM EDT - 3 months ago

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

May 13, 2025, 8:00 AM EDT - 3 months ago

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 7, 2025, 12:45 PM EDT - 3 months ago

Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 3 months ago

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

May 6, 2025, 12:30 PM EDT - 3 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

Apr 30, 2025, 8:00 AM EDT - 3 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Apr 17, 2025, 8:00 AM EDT - 4 months ago

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

Apr 8, 2025, 1:30 PM EDT - 4 months ago

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

Mar 5, 2025, 8:00 AM EST - 5 months ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Mar 3, 2025, 11:53 PM EST - 5 months ago

Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:00 AM EST - 5 months ago

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:05 PM EST - 5 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

Feb 24, 2025, 8:00 AM EST - 5 months ago

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

Feb 11, 2025, 6:08 PM EST - 6 months ago

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 10, 2025, 9:00 AM EST - 6 months ago

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

Jan 13, 2025, 12:56 PM EST - 7 months ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI

Jan 12, 2025, 3:26 AM EST - 7 months ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 8, 2025, 4:15 PM EST - 7 months ago

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Jan 3, 2025, 8:00 AM EST - 7 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Nov 13, 2024, 8:00 AM EST - 9 months ago

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 3:19 PM EST - 9 months ago

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:00 AM EDT - 10 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

Oct 17, 2024, 10:03 AM EDT - 10 months ago

US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 9:41 AM EDT - 10 months ago

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

Aug 9, 2024, 12:27 PM EDT - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Avadel Pharmaceuticals to Join Russell 3000® Index

May 22, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

May 21, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Apr 2, 2024, 3:40 AM EDT - 1 year ago

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Mar 4, 2024, 3:37 PM EST - 1 year ago

Avadel Pharmaceuticals Issues Statement On Patent Litigation

AnthonySaba79 Aug. 8 at 3:45 PM

$AVDL where is this going?

0 · Reply

BlancaAlbertson678 Aug. 8 at 3:14 PM

$AVDL Revenue est for 2025? $20M+ if momentum holds...W.K.S.P scaling right

0 · Reply

Otus Aug. 8 at 3:09 PM

0 · Reply

HoHoHoHum Aug. 8 at 1:23 PM

$AVDL should move and settle down in the 16+ area rather quickly

0 · Reply

Capitulation_0 Aug. 8 at 12:23 PM

1 · Reply

Jusar Aug. 8 at 11:17 AM

$AVDL Nice last minute purchase

0 · Reply

JarvisFlow Aug. 8 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Avadel Pharmaceuticals ( $AVDL ), setting the rating to Buy with a target price of 22 → 24.

0 · Reply

Mrmondial Aug. 8 at 8:13 AM

$AVDL amazing trick to be able to speak out of your a*s

0 · Reply

profitraider Aug. 8 at 4:59 AM

$AVDL Bankrupt in less than a year!

1 · Reply

Capitulation_0 Aug. 7 at 7:58 PM

$AVDL lol, hi shorties..13%. 12m shares

0 · Reply

Capitulation_0 Aug. 7 at 7:18 PM

$AVDL

0 · Reply

Capitulation_0 Aug. 7 at 6:37 PM

$AVDL buyers coming in..

0 · Reply

Capitulation_0 Aug. 7 at 4:15 PM

$AVDL Xywav: $415.3 million for Q2... Lumryz $68M. underserved market. This gap will narrow by how much? Who knows. But superior product should prevail in time w/ management execution.

0 · Reply

Capitulation_0 Aug. 7 at 4:00 PM

$AVDL Listened to the entire cc... I give their performance a C+ Clearly from stock reaction, the market still doesn't think that this management can deliver... Hopefully there will be some upgrades coming. They're profitable and there's no dilution risk. JAZZ grew their narco product 13% despite the headwinds... Lawsuit against JAZZ to recoup 1B starts in Sept. Will probably settle in 10 year ( lol ). The Good New is that they're growing, taking market share and Narcolepsy market is Underserved. I still think they should sell the company to a bigger fish.

1 · Reply

LarryYMB Aug. 7 at 3:45 PM

$AVDL the penny flippers are gone, buy soft one, the long retails are not unhappy, our time will come !

0 · Reply

IOANNISMICHAEL Aug. 7 at 3:36 PM

$AVDL unfortunately ..text book, bad luck for this one. Over extended market - people prefer taking profits, broker sector, recent serious bagholders from 12-16ish $, very unfortunate for a company

0 · Reply

Capitulation_0 Aug. 7 at 3:05 PM

$AVDL became profitable. bio market is broken. How much more did the street expect?

1 · Reply

Otus Aug. 7 at 2:58 PM

$AVDL the stock should be substantially higher based on today’s report and call. Mistrust of management?

1 · Reply

Capitulation_0 Aug. 7 at 2:44 PM

$AVDL Great story brewing. I have no idea why it's selling off but it's an opportunity to add..

0 · Reply

AnthonySaba79 Aug. 7 at 2:44 PM

$AVDL don’t even tell me this can’t even hold $12.. Jesus fn Christ!!

1 · Reply

Capitulation_0 Aug. 7 at 2:19 PM

$AVDL should be at $20.. lol

0 · Reply

valueforme Aug. 7 at 1:40 PM

$AVDL Back. Finally turning the corner

1 · Reply

Market Cap	1.07B
Revenue (ttm)	169.12M
Net Income (ttm)	-48.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	59.91
Profit Margin	-28.87%
Debt to Equity Ratio	0.00

Volume	3,983,600
Avg Vol	1,401,534
Day's Range	N/A - N/A
Shares Out	96.74M
Stochastic %K	61%
Beta	1.47
Analysts	Strong Sell
Price Target	$17.12